OrganiGram Holdings (NASDAQ: OGI) produces and sells medical marijuana, with products including strains, cannabis oils, and vaporizers. It produces its cannabis entirely indoors and on three levels, which increases the actual square feet used for growing space. This aspect of growing indoors leads to, what management believes, a superior-quality product, while also maintaining a low cost of production.
This company is one of only four Canadian cannabis producers with supply agreements with of all Canada’s provinces. A key risk to Organi’s heavy focus on the Canadian market is whether supply will surpass demand in the near future, something some industry observers predict will happen as early as next year. Organi also has expectations to increase its international operations in the future, yet is unable to enter the U.S. marijuana market unless federal laws are changed.